All News
Filter News
Found 2,929 articles
-
The Christiana Care Health System’s Gene Editing Institute, based in Wilmington, Del., is pulling together a preliminary investigational new drug application (IND) for the U.S. Food and Drug Administration (FDA).
-
Top U.S Student Researchers in STEM and Humanities Win Scholarships at the National Junior Science and Humanities Symposium
5/2/2019
The Junior Science and Humanities Symposium is pleased to announce the 2019 winners of the 57th National JSHS competition.
-
Repare Therapeutics Appoints Dr. Maria Koehler as Chief Medical Officer, Katina Dorton as Chief Financial Officer and Carol Schafer to its Board of Directors
5/1/2019
Repare Therapeutics, a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations, announced today that it has made three key additions to its leadership team and Board of Directors
-
Christiana Care’s Gene Editing Institute takes the next step toward its first investigational drug application for FDA approval to treat lung cancer using CRISPR
4/30/2019
Gene Editing Institute’s study will be a novel investigation of the use of CRISPR technology to treat K-ras-positive non-small cell lung cancer
-
Vertex Reports First-Quarter 2019 Financial Results
4/30/2019
First-quarter 2019 product revenues of $857 million, a 34% increase compared to $638 million in 2018
-
Horizon Discovery Group plc: Full Year Results for the Year Ended 31 December 2018
4/29/2019
Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a global leader in the application of gene editing and gene modulation technologies, today announces its full year results for the year ended 31 December 2018.
-
Magenta Therapeutics to Present Preclinical Data on E478 Stem Cell Gene Therapy Expansion Program at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy
4/29/2019
Developing novel methods to expand gene-modified stem cells to achieve higher cell doses
-
Avellino Labs Expands Medical Advisory Board with Internationally-Renown Ophthalmologists
4/29/2019
Ophthalmic Opinion Leaders to Shape the Next Generation in Personalized Medicine with Company’s Genetic Diagnostic and Therapeutic Technologies
-
CANbridge Pharmaceuticals Appoints Chief Financial Officer and Interim Chief Medical Officer - April 26, 2019
4/26/2019
CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that it has appointed Glenn Hassan to the position of Chief Financial Officer and Chief Business Officer, and Gerald F.
-
Companies across Europe and Asia provide information about deal, clinical trials and more, with news from Synaptive Medical, Epic, Inventiva, Velabs, and more.
-
Applied StemCell Therapeutics Cures Hemophilia A in Mice
4/25/2019
Applied StemCell, Inc. announced that its therapeutic division has cured Hemophilia A in mice and will be presenting their in vivo and in vitro findings at the 22nd Annual Meeting of The American Society of Gene and Cell Therapy held April 29 – May 2 in Washington D.C.
-
Eight Student Teams Named National Winners of 27th Annual ExploraVision Competition
4/25/2019
Toshiba and the National Science Teachers Association (NSTA) Honor Student Innovation with Prizes and Trip to Washington, D.C.
-
CANbridge Pharmaceuticals Appoints Chief Financial Officer and Interim Chief Medical Officer - April 25, 2019
4/25/2019
CANbridge Pharmaceuticals Inc. announced that it has appointed Glenn Hassan to the position of Chief Financial Officer and Chief Business Officer, and Gerald F. Cox, MD, PhD, as Chief Development Strategist and interim Chief Medical Officer, effective as of April.
-
Emendo Biotherapeutics Enters Into Licensing Option Agreement With Takeda for its OMNI Nuclease Program
4/24/2019
The funds will be used to further advance Emendo's novel nuclease gene editing discovery platform and proprietary product development programs.
-
Casebia Advances Genetic Engineering with New Tools and Techniques
4/24/2019
Ten abstracts that will be presented at ASGCT 2019 showcase the company’s innovative approach as it advances a broad array of gene editing programs
-
University of California Granted New CRISPR-Cas9 U.S. Patent, Further Expanding Patent Portfolio for Genome Editing
4/23/2019
New U.S. patent, involved in prior terminated interference proceeding, is fourth patent issued to UC covering CRISPR-Cas9 gene editing
-
Genetics Research LLC & UNH Publish Paper in PLOS ONE on Novel CRISPR/Cas9 Associated Method for Nucleic Acid Enrichment
4/23/2019
These novel and valuable findings are based on the patented and patent-pending technology of GR, an inventor of innovative technologies for the development of products for genomic analysis in research, diagnostics, and companion diagnostics.
-
New Method to Detect Off-Target Effects of CRISPR
4/19/2019
Since the CRISPR genome editing technology was invented in 2012, it has shown great promise to treat a number of intractable diseases.
-
Parent Project Muscular Dystrophy Awards $100,000 Grant to Nationwide Children's Hospital to Further Explore GALGT2 Gene Therapy in Duchenne Muscular Dystrophy
4/18/2019
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced that Drs. Paul Martin and Kevin Flanigan from the Research Institute at Nationwide Children's Hospital have completed work under a $100,000 grant exploring GALGT2 gene therapy technology as a potential treatment for Duchenne.
-
St. Jude Children’s Research Hospital publishes results of Lentiviral Gene Therapy for Treatment of Infants with X-linked Severe Combined Immunodeficiency in New England Journal of Medicine
4/18/2019
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that the New England Journal of Medicine has published data from St. Jude Children’s Research Hospital (“St. Jude”), the nation’s leading hospital dedicated to understanding, treating and curing childhood cancer and other life-threatening diseases.